Pratia LLC, part of Humaneva Group, has acquired a majority stake in P1 Trials, a U.S.-based early‑phase oncology clinical research network, creating a transatlantic collaboration to expand patient access to innovative cancer therapies.
P1 Trials operates community‑based oncology practices in Washington, Texas and Indiana, enabling advanced early‑phase studies to be conducted closer to where patients receive care. The company provides the infrastructure and support needed for community oncology practices to run early‑phase trials under a unified global standard.
The investment establishes one of the few global research ecosystems focused exclusively on early‑phase oncology, connecting North America and Europe to accelerate development of next‑generation cancer treatments. Both organizations emphasize a patient‑centric approach and aim to bring innovative therapies to patients in their own communities.
Pratia currently reaches more than 65 million patients across Europe through its integrated oncology research sites. Adding P1’s U.S. network extends that reach and enhances the combined ability to deliver innovative studies in the world’s largest oncology research market.
The transaction strengthens Pratia’s presence in the United States and underscores its commitment to accelerating treatment development through closer collaboration with practicing oncologists.
According to the American Association for Cancer Research, about 18.6 million cancer survivors were living in the U.S. as of January 2025, while the World Health Organization estimates 3.7 million new cancer cases annually across Europe.
“The partnership with Pratia enables us to deliver a truly homogeneous research experience across continents,” said Julio Peguero, MD, President of P1 Trials. “By unifying our scientific rigor, operational standards and patient care models, we’re building a seamless early‑phase oncology network that operates with the same precision and excellence — from community practices in the U.S. to leading research centers across Europe. This alignment accelerates innovation and ensures patients everywhere gain faster access to tomorrow’s therapies.”
“P1’s mission has always been to bridge the gap between research and everyday oncology care, ensuring patients have access to pioneering treatments close to home,” said Ron Carozza, PharmD, CEO of P1 Trials. “We share the same values as Pratia, and with their global expertise and resources, we can accelerate this mission even further. Together, we will bring the latest cancer science directly to patients in their communities — faster.”
The unified early‑phase network aims to address the urgent global need for faster development and wider access to innovative therapies.
About Pratia
Pratia, part of the Humaneva Group, is one of Europe’s largest clinical research site networks, operating more than 100 research sites across multiple therapeutic areas with a strong focus on oncology. Pratia partners with sponsors, CROs and healthcare providers to integrate clinical research into everyday care and expand access to innovative treatments for diverse patient populations. www.pratia.com
About P1 Trials
P1 Trials is a U.S.-based clinical research network specializing in early‑phase oncology studies. By partnering with community oncology practices, P1 Trials brings advanced research opportunities directly to patients, enabling faster access to next‑generation cancer therapies close to home. www.p1trials.com
About Humaneva Group
Humaneva Group is the parent company of Pratia.
Leave a Reply